Olanzapine (Zyprexa) and Fluoxetine Combination
When combining olanzapine with fluoxetine, start with 5 mg olanzapine plus 20 mg fluoxetine once daily in the evening for adults, with dose adjustments based on response up to 12.5 mg/50 mg for bipolar depression or 20 mg/50 mg for treatment-resistant depression 1.
FDA-Approved Dosing Recommendations
The combination is FDA-approved for two specific indications 1:
Bipolar I Depressive Episodes (Adults)
- Starting dose: 5 mg olanzapine + 20 mg fluoxetine once daily
- Effective range: 6-12 mg olanzapine + 25-50 mg fluoxetine
- Maximum studied: 18 mg olanzapine + 75 mg fluoxetine (safety not established beyond this)
- Administer in the evening, without regard to meals
Treatment-Resistant Depression (Adults)
- Starting dose: 5 mg olanzapine + 20 mg fluoxetine once daily
- Effective range: 6-18 mg olanzapine + 25-50 mg fluoxetine
- Maximum studied: 20 mg olanzapine + 50 mg fluoxetine
Pediatric Dosing (Ages 10-17, Bipolar Depression Only)
- Starting dose: 2.5 mg olanzapine + 20 mg fluoxetine
- Maximum studied: 12 mg olanzapine + 50 mg fluoxetine 1
Critical Safety Concerns
Metabolic Effects (Primary Concern)
The combination causes significant weight gain and metabolic disturbances that limit its use as first-line therapy 2:
- Mean weight gain: 4.8 pounds after 7 weeks, 6.3-10.7 pounds after 19 weeks 3
- 33-50% of patients experience ≥7% weight increase 3
- Monitor for hyperglycemia, diabetes, dyslipidemia, and metabolic syndrome 1, 2
- Obtain baseline and periodic fasting glucose, lipid panels, and weight measurements
Pharmacokinetic Drug Interaction
Fluoxetine significantly increases olanzapine exposure through P-glycoprotein inhibition 4:
- Olanzapine Cmax increases 5-fold (44.1 vs 9.0 ng/mL)
- AUC increases 5-fold (235.8 vs 47.5 h×ng/mL)
- Clearance decreases 6-fold
- This interaction is the mechanistic basis for using lower olanzapine doses in combination than as monotherapy
CYP2D6 Genetic Considerations
Poor metabolizers (PMs) of CYP2D6 are at substantially higher risk for fluoxetine toxicity 5:
- Single-dose fluoxetine AUC is 3.9-11.5 fold higher in PMs versus extensive metabolizers
- Long-term fluoxetine (20 mg/day) converts 43% of normal metabolizers to PM phenotype through auto-inhibition
- FDA warns about QT prolongation risk in CYP2D6 PMs taking fluoxetine
- Fatal cases reported: A 9-year-old CYP2D6 PM on high-dose fluoxetine (80-100 mg/day) died from metabolic toxicity, seizures, and cardiac arrest 5
Cardiovascular Risks
- QT prolongation: Use with caution in patients with congenital long QT, family history of sudden cardiac death, or CYP2D6 PM status 5
- Orthostatic hypotension: Monitor blood pressure, especially in elderly or debilitated patients 1
Other Serious Adverse Events
- Neuroleptic malignant syndrome (rare but potentially fatal)
- Tardive dyskinesia with chronic use
- Seizure risk (particularly relevant given the fluoxetine case fatality) 5
- Increased mortality in elderly patients with dementia-related psychosis (black box warning) 1
Efficacy Evidence
The combination is more effective than monotherapy for both approved indications 6:
- MADRS score improvement: 3.37 points greater than monotherapy (P<0.001)
- Response rate: 35% higher (RR=1.35)
- Remission rate: 71% higher (RR=1.71)
- Benefits maintained for at least 6 months with continuation treatment 7
Switching from combination to olanzapine monotherapy causes symptom worsening 3:
- MADRS scores increased by 8.2 points when switched to olanzapine alone
- Only 12.5% maintained response versus 31.3% on continued combination
- Continue the combination if effective rather than switching to monotherapy
Common Pitfalls to Avoid
Don't use olanzapine monotherapy for bipolar depression - it's not FDA-approved and less effective than the combination 1
Don't combine with benzodiazepines intramuscularly - diazepam causes precipitation; lorazepam delays reconstitution 1
Don't ignore baseline metabolic screening - the weight gain and metabolic effects are predictable and substantial
Don't use doses below 6 mg/25 mg for maintenance - the 1 mg/5 mg dose is ineffective 8
Don't overlook CYP2D6 status in high-risk patients - consider genetic testing before using high fluoxetine doses, especially in patients with cardiac risk factors or seizure history 5
Don't abruptly discontinue in responders - taper gradually as bipolar disorder requires chronic treatment 1